We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) (AHC-SO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00931164
Recruitment Status : Completed
First Posted : July 2, 2009
Results First Posted : March 31, 2014
Last Update Posted : March 31, 2014
Alternating Hemiplegia of Childhood Foundation
Jazz Pharmaceuticals
Information provided by (Responsible Party):
Kathryn Swoboda, University of Utah

Brief Summary:

WHO: The investigators are recruiting children and young adults to participate in a research study who:

  1. Have been diagnosed with Alternating Hemiplegia of Childhood (AHC)
  2. Are between the ages of 6 months - 25 years old
  3. Have at least three 10-minute-long AHC episodes during a typical week
  4. Can commit to 12 weeks of completing of a daily log describing AHC episodes and to a multi-night hospital stay at the University of Utah Center for Clinical and Translational Science (CCTS)

WHY: The goal of this study is to evaluate whether the study drug can safely and effectively decrease AHC episodes and improve the quality of life of individuals with AHC.

WHAT and WHERE: This study involves at least 12 weeks of completing and submitting daily AHC Episode Logs and a five-day hospital stay at the University of Utah CCTS.

There are 4 phases of the study, and they include:

  1. Six weeks of daily log completion prior to starting study drug
  2. Five day stay at the University of Utah CCTS
  3. Six additional weeks of daily log completion while using study drug at home
  4. One day clinic visit to the University of Utah for follow up


There is no fee to participate. All procedures performed specifically for this study will be covered by the study and will not be billed to you or your insurance company.

The study drug will be dispensed to you free of charge. Meals and lodging at the study site will be provided free of charge for the study participant and one care provider. Additionally, the research team will assist subjects with booking and obtaining free transportation, such as an airline tickets, to and from the study site.

Condition or disease Intervention/treatment Phase
Alternating Hemiplegia of Childhood Drug: Sodium Oxybate Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)
Study Start Date : August 2009
Actual Primary Completion Date : January 2011
Actual Study Completion Date : September 2011

Arm Intervention/treatment
Experimental: Sodium oxybate
  • The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
  • Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy.
Drug: Sodium Oxybate
dosage is by weight

Primary Outcome Measures :
  1. Time Duration of AHC Episodes [ Time Frame: Week 7 ]
  2. Observed Safety Data During 5-day Hospitalization for Drug Dose Identification [ Time Frame: Week 7 ]
  3. Number of Participants Who Reported Side Effects During Home Drug Maintenance Phase [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Mean Daily Percentage of Time That Functional Status is Affected Due to Episodes [ Time Frame: Week 14 ]
  2. Quality of Life Questionnaires [ Time Frame: Week 14 ]
  3. Mood and Behavior Questionnaires [ Time Frame: Week 14 ]
  4. Functional Skills Questionnaires [ Time Frame: Week 14 ]
  5. Neuropsychological Tests [ Time Frame: Week 14 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria.

  • AHC classic criteria:

    • Onset of symptomatology prior to 18 months of age
    • Repeated attacks of hemiplegia involving either side of the body
    • Paroxysmal disturbances, including tonic or dystonic spells, oculomotor abnormalities, and various autonomic phenomena, during hemiplegic bouts or in isolation
    • Episodes of bilateral hemiplegia or quadriplegia starting either as generalization of a hemiplegic episode or bilateral from the beginning
    • Immediate disappearance of symptoms upon sleeping, with possible resumption 10-20 minutes after waking
    • Evidence of developmental delay and neurologic abnormalities including choreoathetosis, dystonia, or ataxia

In addition:

  • Provision of a complete daily event log for 6 weeks prior to initiation of sodium oxybate therapy, including the: (1) frequency, (2) duration, (3) type, (4) severity of episodes, and (5) therapies, if any, used in an attempt to abort the episode
  • Ages 6 months to 25 years at the time of study enrollment
  • Minimum of 3 AHC episodes weekly, lasting at least 10 minutes each, on average prior to study enrollment
  • Brain neuroimaging studies excluding alternative etiology for symptoms
  • Documented absence of epileptiform features on EEG during typical ictal events
  • Ability of primary caregivers of study participants to submit online daily AHC Episode Logs indicating frequency and duration of ictal episodes over the entire study period
  • Written informed consent from parents/guardians and assent from children 7 years or older
  • Girls/women > 12 years of age will be required to be on birth control continuously if they are considered at risk to become pregnant. Those not on birth control will be required to have a screening pregnancy test at baseline, and to confirm their willingness to practice birth control or abstain from sexual activity for the duration of treatment with study medication.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation.

  • History of hepatic insufficiency, renal insufficiency, significant respiratory disease, cardiac arrhythmia, congenital heart defect, hypertension, or ischemic stroke
  • History of allergy/sensitivity to sodium oxybate
  • Use of sodium oxybate within 30 days of study enrollment
  • Serious illness requiring systemic treatment and/or hospitalization within two weeks prior to study enrollment
  • Change in neurologic medication regimen within 30 days of study enrollment.
  • Inability to stay at the Center for Clinical and Translational Science (CCTS) for 5 days due to behavioral issues
  • Unwillingness or inability to travel to study site during the necessary 1 week titration period to determine the most appropriate dose of GHB for subsequent administration
  • Noncompliance with AHC Episode Log or study visit requirements
  • Sleep apnea not adequately treated with C-PAP and oxygen saturation monitoring prior to drug therapy initiation
  • Succinic semialdehyde dehydrogenase deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00931164

Layout table for location information
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Utah
Alternating Hemiplegia of Childhood Foundation
Jazz Pharmaceuticals
Layout table for investigator information
Principal Investigator: Kathryn J. Swoboda, M.D. University of Utah/Primary Children's Medical Center
Bourgeois M, Aicardi J. The treatment of alternating hemiplegia of childhood with flunarizine: experience with 17 patients. Alternating Hemiplegia of Childhood, edited by F Andermann, J Aicardi, and F Vigevano. 1995;191-194.
Katchan B, Mamelak M, Hwang P. Alternating Hemiplegia of Childhood: Rationale for the use of Gammahydroxybutyrate, Reprints from the 10th International Child Neurology Congress, Montreal, June 2006.
Ricci S. Sleep studies of children with alternating hemiplegia of childhood. Alternating Hemiplegia of Childhood, edited by Andermann, Aicardi, and Vigevano. 1995;95-98.
Silver K, Andermann F. Alternating hemiplegia of childhood: treatment with flunarizine. Alternating Hemiplegia of Childhood, edited by F Andermann, J Aicardi, and F Vigevano. 1995;195-198.

Layout table for additonal information
Responsible Party: Kathryn Swoboda, Associate Professor, Neurology and Pediatrics Director, Pediatric Motor Disorders Research Program, University of Utah
ClinicalTrials.gov Identifier: NCT00931164    
Other Study ID Numbers: 32164
First Posted: July 2, 2009    Key Record Dates
Results First Posted: March 31, 2014
Last Update Posted: March 31, 2014
Last Verified: March 2014
Keywords provided by Kathryn Swoboda, University of Utah:
phase I/II study
effects of sodium oxybate
cohort of 6 children and young adults
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurologic Manifestations
Nervous System Diseases
Sodium Oxybate
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs